New capital infusion for QbDVision secured through top-tier enterprise customer acquisitions, successful global deployments, and demand for rapid digitalization of work streams across the entire product lifecycle.
Industry growth and momentum is driving unprecedented demand for CMC transformation. With the realization that data-only strategies are not sufficient, the shift to knowledge-based business processes to improve operational efficiency is happening across the industry.
QbDVision is the force behind this fundamental shift and further solidifying them as the Chemistry, Manufacturing, and Controls (CMC) knowledge backbone to enhance operational efficiency and enable tomorrow’s AI-powered pharmaceutical industry.
To accelerate growth and solidify its market leadership, QbDVision strategically appoints Mike Stapleton as Chief Business Officer and Chas Peacock as VP of Engineering
QbDVision is poised to navigate today’s market uncertainty, regulatory flux, and supply chain disruption, empowering a smarter, more agile future for biopharma.
Digital CMC has gone mainstream
After a year of breakthrough successes, QbDVision has secured $13M in additional investment fueled by rapid enterprise customer growth, successful global deployments, and an increased demand for digitalization of work streams across the entire product lifecycle for pharma and biotech.
Led by prior investors Northpond Ventures and S3 Ventures, along with other company insiders, this new capital infusion accelerates the realization of our shared vision and the opportunity at hand: solidifying QbDVision as the digital knowledge backbone of Chemistry, Manufacturing, and Controls (CMC) workflows for tomorrow’s AI-powered pharmaceutical industry.
Industry Momentum: CMC transformation takes center stage
The industry is now at a tipping point and CMC has hit center stage for digital transformation. Drug sponsors are re-engineering CMC workflows and business processes to reduce the lifecycle of development. We’re seeing regulatory bodies working on structured CMC data and knowledge initiatives to accelerate the review of submissions. International organizations and industry groups are prioritizing data standards (e.g., taxonomy or ontologies). With the realization that data-only strategies are not sufficient, the shift to knowledge-based business processes to improve operational efficiency is happening across the industry.
“CMC knowledge is a key asset for any company developing new therapies”, Yash Sabharwal, President, CEO, and Co-Founder at QbDVision notes. “As organizations look for ways to accelerate the development of complex modalities and navigate both regulatory and market uncertainty, they need contextualized understanding of their CMC operations and QbDVision is increasingly the solution of choice to meet this need.”
Further, as the world economy moves away from globalization and more manufacturing activities are onshored, the ability to manage and transfer CMC knowledge quickly will become even more critical. This is yet another reason why leading enterprise companies continue to select QbDVision to accelerate CMC digital transformation within their organizations.
CMC Knowledge: The catalyst to unlock operational excellence and AI’s true potential
QbDVision has enabled the first fundamental shift required for digital transformation. A movement away from siloed, document-centric legacy approaches and towards an integrated platform where CMC data is converted into information and knowledge. QbDVision is the force that can finally bring down the old barriers between teams, sites, organizations, and regulatory agencies.
“We are following the same path for CMC operations that was taken by the discovery world to build the AlphaFold models for prediction and optimization of proteins,” Yash notes. “AlphaFold was not trained directly on lots of data from the internet, it was trained on using low volume, highly curated knowledge models of protein structure and function. This is fundamental to QbDVision’s initial design and why we’re the solution of converting CMC data models into structured, curated and domain-specific knowledge models.”
In essence, just as AlphaFold required specific, reliable scientific information to solve a complex problem, unlocking the power of AI in drug development demands the same trustworthy, highly-contextualized CMC knowledge that QbDVision delivers.
“It’s the knowledge backbone that unlocks tomorrow’s AI-powered industry,” affirms [ insert name ], Partner at Northpond Ventures. “That’s what makes it so exciting to further our partnership with QbDVision. Their innovative platform combined with their pioneering vision can fundamentally alter the way our industry executes. Laying the foundation for intelligent, AI-powered pharma operations built on CMC knowledge. A shared source of truth that spans the entire product life cycle and can unlock an organization’s true potential.”
Scaling Up: Key management hires to accelerate growth and solidify market leadership
To meet increasing market demand and capitalize on significant growth opportunities, QbDVision has strategically bolstered its leadership team with the appointment of two key executives.
A digital pioneer and leading voice in life science innovation who needs no introduction, Mike Stapleton is stepping up from QbDVision’s board into a key leadership position as Chief Business Officer, where he’s already played a key role, now he’ll play a pivotal role in expanding our strategic agenda and forging new growth opportunities.
“From my experience on the board, I’ve seen QbDVision’s tremendous potential. Moving into this role full-time allows me to directly contribute to and accelerate our strategic vision, ensuring we capitalize fully on our market momentum,” Mike notes. “This strategic investment allows us to aggressively scale key enterprise accounts and solidify our market leadership.”
At the same time, recognizing the need to prepare our product and engineering capabilities for rapid scale, Chas Peacock was hired as VP of Engineering. “Reflecting on ensuring the best possible product experience for QbDVision customers while scaling a highly technical team, Chas emphasized, “successfully scaling an engineering team isn’t just about hiring more people, it’s about building a culture that allows innovation to flourish. We’re focusing on attracting talented individuals who are motivated by our mission, and ensuring they have the resources they need to thrive.”
QbDVision is entering its next phase of growth by laying the groundwork for an organization that’s continuing to lead the Digital CMC movement and help the world’s most innovative drug developers bring therapies to patients with greater speed and certainty.
What’s next: Empowering a smarter, more agile future for biopharma
This funding isn’t just a win for us—it’s a clear signal that Digital CMC is becoming essential infrastructure for biopharma. It accelerates our journey to build the digital foundation for the future of medicine. Transforming CMC data from a historical bottleneck into a strategic asset. Paving the way for faster innovation, enhanced industry collaboration and ultimately getting critical therapies to patients sooner.
As the life sciences landscape continues to face unprecedented market volatility, evolving regulatory expectations, and growing supply chain disruption, QbDVision can offer organizations the ability to not only adapt quickly to these market conditions —but thrive in them.
Media inquiries
About QbDVision
QbDVision is a structured, cloud-based platform designed to empower teams with unified knowledge of their product and manufacturing process, while automating key development workflows throughout the entire product lifecycle journey. Unlike other traditional product lifecycle management (PLM) solutions, QbDVision’s Digital CMC platform is purpose-built for biopharma organizations to accelerate the development of life-changing therapies as they transition from R&D to Commercial Manufacturing. Teams can now leverage robust CMC knowledge that provides real-time guidance for enhanced data-driven decision making and streamlines complex operational workflows that reduces cycle times, while ensuring quality and compliance.
Learn more >
GET IN TOUCH
Ready to join our journey?
It’s about to enter a new powerhouse phase. Want to be part of it? Visit our careers page to explore opportunities to join our growing team.
